Abivax KOL takeaways: uniquely differentiated
We hosted a KOL call focused on Obefazimod (Abivax) with Prof. Yoram Bouhnik, head of the Paris IBD center and author of over 300 peer-reviewed publications on IBD. Prof. Bouhnik, participated in Obefazimod Phase IIb (11 patients enrolled) and in current Phase III (17 enrollees).Key takeaways from
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.